Key facts
- This page summarizes Patrick D. Spangler's Form 4 filing for OptimizeRx Corp (OPRX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Jun 2024, 17:50.
Patrick D. Spangler - 05 Jun 2024 Form 4 Insider Report for OptimizeRx Corp (OPRX)
- Reporting relationship
- Director
- Issuer ticker
- OPRX
- Reported as of
- 05 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 Jun 2024, 17:50:28 UTC
- Prior SEC filing
- 18 Aug 2023
- Next SEC filing
- 12 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marion Odence-Ford, by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick D. Spangler filed Form 4 for OptimizeRx Corp (OPRX) on 11 Jun 2024.
Change
- Previous filing in this sequence was filed on 18 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OPRX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +10,061
- Change %
- +45%
- Price
- $0.000000
- Shares after
- 32,181
- Date
- 05 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
OPRX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +13,286
- Change %
- +41%
- Price
- $0.000000
- Shares after
- 45,467
- Date
- 07 Jun 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OPRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -10,061
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 05 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,061
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Restricted stock units convert into common stock on a one-for-one basis.
Footnote F2
Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders.
Footnote F3
On June 7, 2023 the reporting person was granted 10,061 restricted stock units which vested in full on June 5, 2024.
SEC remarks
The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.